SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Rule 2.9 Announcement

18 Jul 2018 14:49

RNS Number : 0654V
Consort Medical PLC
18 July 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

 

For immediate release

18 July 2018

 

Consort Medical plc

("Consort" or the "Company")

 

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of the Code, Consort confirms that it has today issued 764 shares and therefore, as at the date of this announcement, it has issued share capital consisting of 49,289,382 ordinary shares of 10 pence each.

 

The increase in issued share capital is the result of Consort share options being exercised by a former employee. The shares issued upon exercise of the options were admitted for trading on the Main Market of the London Stock Exchange as part of the block admission update announced on 27 June 2013.

 

There are no ordinary shares held in treasury. The ordinary shares trade on the Main Market of the London Stock Exchange. The International Securities Identification Number (ISIN) of the ordinary shares is GB0000946276.

 

The Company has an American Depositary Receipt ("ADR") programme for which The Bank of New York Mellon acts as depositary. One ADR represents one ordinary share in the Company, with ISIN US21030P1049. The ADRs trade in the over-the-counter market in the United States and are not listed on any national US securities exchange.

 

Enquiries:

 

Consort Medical plc

+44 (0) 1442 867 920

Jonathan Glenn - Chief Executive Officer

Paul Hayes - Chief Financial Officer

 

Disclosure Requirements of the Code

 

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

 

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

 

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0) 207 638 0129.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RTTRPMJTMBIBBRP
Date   Source Headline
15th Jun 20123:12 pmRNSDirector/PDMR Shareholding
14th Jun 20127:00 amRNSDirectorate
14th Jun 20127:00 amRNSPreliminary Results
6th Jun 20121:57 pmRNSBlocklisting Interim Review
1st May 201210:21 amRNSTotal Voting Rights
30th Apr 20127:00 amRNSFDA Approval Proprietary Integrated Dose Counter
20th Apr 201210:54 amRNSHolding(s) in Company
16th Apr 201211:37 amRNSBlocklisting Interim Review
28th Mar 20124:36 pmRNSHolding(s) in Company
22nd Mar 20129:58 amRNSAnnual Information Update
20th Mar 20124:25 pmRNSReplacement Interim Management Statement
20th Mar 20121:07 pmRNSInterim Management Statement
1st Mar 20129:00 amRNSTotal Voting Rights
17th Feb 201210:09 amRNSHolding(s) in Company
23rd Jan 20129:45 amRNSBlocklisting Interim Review
13th Dec 20112:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20111:34 pmRNSBlocklisting Interim Review
1st Dec 20117:00 amRNSInterim results for the six months ended 31/10/11
19th Oct 20114:03 pmRNSHolding(s) in Company
17th Oct 20113:13 pmRNSHolding(s) in Company
14th Oct 20119:39 amRNSBlocklisting Interim Review
7th Oct 201112:13 pmRNSHolding(s) in Company
5th Oct 20114:47 pmRNSHolding(s) in Company
4th Oct 20117:00 amRNSSecond Nasal Drug Delivery Contract
27th Sep 20114:33 pmRNSHolding(s) in Company
26th Sep 20113:01 pmRNSHolding(s) in Company
2nd Sep 201110:21 amRNSTotal Voting Rights
1st Sep 20112:50 pmRNSResult of AGM
1st Sep 20112:47 pmRNSDirectorate Change
1st Sep 201112:40 pmRNSInterim Management Statement
1st Sep 20117:00 amRNSNasal Drug Delivery Contract
24th Aug 20114:35 pmRNSHolding(s) in Company
2nd Aug 20111:51 pmRNSDirector/PDMR Shareholding
2nd Aug 20111:47 pmRNSDirector/PDMR Shareholding
28th Jul 20119:14 amRNSAnnual Financial Report
20th Jul 20117:00 amRNSFurther re Investment in Atlas Genetics
30th Jun 20111:58 pmRNSTotal Voting Rights
24th Jun 20119:06 amRNSHolding(s) in Company
21st Jun 201112:33 pmRNSBlocklisting Interim Review
16th Jun 20117:00 amRNSPreliminary results for the year ended 30/04/11
2nd Jun 20117:00 amRNSBlocklisting Interim Review
10th May 20119:27 amRNSHolding(s) in Company
14th Apr 201110:20 amRNSBlocklisting Interim Review
4th Apr 201110:29 amRNSHolding(s) in Company
1st Apr 20111:51 pmRNSHolding(s) in Company
23rd Mar 20112:04 pmRNSAnnual Information Update
14th Mar 20117:00 amRNSInterim Management Statement
15th Feb 20114:14 pmRNSHolding(s) in Company
9th Feb 201111:15 amRNSDirectorate Change
7th Feb 20117:00 amRNSPartners with Atlas Genetics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.